A Look at the Highlights from Phase 1 of the 139th Canton Fair
GUANGZHOU, China, April 14, 2026 /PRNewswire/ -- Focusing on Advanced Manufacturing, Phase 1…
ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
$LOL Announces Next Expansion Phase Ahead of 2026 Memecoin Cycle
DUBAI, United Arab Emirates, April 04, 2026 (GLOBE NEWSWIRE) -- As the…
Hyatt Advances Next Phase of Growth in India and Southwest Asia with New Senior Leadership Appointment
Appointment of Vikas Chawla builds on significant growth with nearly 5,000 rooms…
Tejas Networks completes delivery of 17,000 IP/MPLS routers for BharatNet Phase III
BENGALURU, India, March 30, 2026 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE:…
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe…
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
March 28, 2026 15:00 ET | Source: Roivant Sciences The results of…
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
March 27, 2026 10:30 ET | Source: Celldex Therapeutics, Inc. - Improvements…
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcytes 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026 19:34 ET | Source: Vaxcyte, Inc. Based on the…
Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026
SAN CARLOS, Calif., March 14, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc.…
